Drug Discovery
Drug Discovery is an emerging pharmacological science that seeks to identify novel small molecule probes and to understand at a molecular level how compounds affect macromolecular process. Cell-based, in vitro mix-and-read, and whole organism assays suitable for rapid or high throughput analysis are being designed and implemented by members of the Molecular Pharmacology Program. Current molecular targets include Gprotein coupled receptors, vanilloid receptors, cathepsins, apoptosis-inducing proteins, ion channels, steroid receptors, orphan nuclear receptors, kinases, phosphatases, DNA repair enzymes, and DNA polymerases. Chemical libraries and automated screening instrumentation are emphasized, which permit rapid interrogation of optimized assays. Computational approaches and high content cell screening methodologies are employed to facilitate the identification of new chemical probes.

Faculty

bayihx@upmc.edu
412-692-5164
lbirder@pitt.edu
412-383-7368
cheny1@pitt.edu
412-624-5444
curran@pitt.edu
412-624-8240
freerad@pitt.edu
412-648-9319
yuj5@pitt.edu
412-648-3390
pagano@pitt.edu
412-383-6505
mjp44@pitt.edu
412-383-5900
fjs2@pitt.edu
412-648-0193
svs2@pitt.edu
412-623-3262
tsmithga@pitt.edu
412-648-8106
vanhoutenb@upmc.edu
412-623-7762
qjw1@pitt.edu
412-383-7754
wangz2@upmc.edu
412-623-3903
pwipf@pitt.edu
412-624-8606
zhanglx@upmc.edu
412-623-1009

Student News



Events

Molecular Pharmacology Journal Club
Dennis Braden
Thomas E. Starzl Biomedical Science Tower
1395 Conference Room

Recent Publications

Program Achievements

Molecular Pharmacology Graduate Program Ranked #2 in National Research Council Rankings

Outcomes: 

Time to dissertation Defense
, last five graduating classes:  4.6 years, Completion Rate: 86.49%

First Author Publications (All students, past 5 year mean):  2.03;   Total Publications: 5.10

F-series Grants (F30/F31) (All Students, past 5 year mean):  12/34 (35%) 


Ranked #9 in National of Institute of Health funding of departments of Pharmacology

Ranked in the top 15 in funding for twenty-four consecutive years